Our Partners: Boehringer Ingelheim and Dicerna Pharmaceuticals

Learn about our collaboration with Dicerna to develop novel treatments for liver diseases, including NASH

More related content

PRESS RELEASE 02 Nov 2017 at 11:30

Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Read more on

Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH)
Partnering in CardioMetabolic Diseases

Therapeutic Areas

Partnering in CardioMetabolic Diseases

Read moreon

Partnering in CardioMetabolic Diseases